Event Brief
Neurocrine nears $2.5bn deal for obesity treatment
Filed: Apr 06, 2026 at 12:03 AM ET
Summary: Neurocrine Biosciences is close to acquiring Soleno Therapeutics, which developed a drug for Prader-Willi syndrome.
WHO: Neurocrine Biosciences
WHAT: Acquisition of Soleno Therapeutics
WHEN: Apr 05, 2026 at 10:47 PM ET
WHERE: USA
WHY: Part of a strategic move to enhance their product portfolio in obesity treatment.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →